Literature DB >> 27425155

Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy.

Hala Yamout1, George L Bakris2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27425155     DOI： 10.1038/nrneph.2016.109

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  8 in total

Review 1.  Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.

Authors:  Raymond V Oliva; George L Bakris
Journal:  J Am Soc Hypertens       Date:  2014-02-12

2.  Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

Authors:  David Z I Cherney; Bruce A Perkins; Nima Soleymanlou; Maria Maione; Vesta Lai; Alana Lee; Nora M Fagan; Hans J Woerle; Odd Erik Johansen; Uli C Broedl; Maximilian von Eynatten
Journal:  Circulation       Date:  2013-12-13       Impact factor: 29.690

3.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

4.  Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

Authors:  Ilkka Tikkanen; Kirsi Narko; Cordula Zeller; Alexandra Green; Afshin Salsali; Uli C Broedl; Hans J Woerle
Journal:  Diabetes Care       Date:  2014-09-30       Impact factor: 19.112

5.  Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

Authors:  Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden J Manns; Scott Klarenbach; Neesh Pannu; Matthew T James; Brenda R Hemmelgarn
Journal:  Lancet       Date:  2012-06-19       Impact factor: 79.321

6.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

7.  Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.

Authors:  Sophia Zoungas; John Chalmers; Bruce Neal; Laurent Billot; Qiang Li; Yoichiro Hirakawa; Hisatomi Arima; Helen Monaghan; Rohina Joshi; Stephen Colagiuri; Mark E Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Liu Lisheng; Giuseppe Mancia; Michel Marre; David R Matthews; Carl E Mogensen; Vlado Perkovic; Neil Poulter; Anthony Rodgers; Bryan Williams; Stephen MacMahon; Anushka Patel; Mark Woodward
Journal:  N Engl J Med       Date:  2014-09-19       Impact factor: 91.245

8.  Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats.

Authors:  Kazi Rafiq; Yoshihide Fujisawa; Shamshad J Sherajee; Asadur Rahman; Abu Sufiun; Hiroyuki Kobori; Hermann Koepsell; Masaki Mogi; Masatsugu Horiuchi; Akira Nishiyama
Journal:  Diabetologia       Date:  2015-10-08       Impact factor: 10.122
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.